Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 278

1.

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus.

Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, Dolstra H, Lankester AC, Mohty M, Montoto S, Peffault de Latour R, Snowden JA, Styczynski J, Yakoub-Agha I, Kröger N; European Society for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2020 Feb 17. doi: 10.1038/s41409-020-0826-4. [Epub ahead of print]

PMID:
32066864
2.

[Reporting data of patients receiving CAR T cell therapy into the EBMT registry: Guidelines of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Vasseur A, Karam M, Chaillou D, Colonnese E, Dantin C, Latiere C, Meziane Y, Pereira M, Yakoub-Agha I, Chabannon C, Raus N.

Bull Cancer. 2019 Dec 9. pii: S0007-4551(19)30375-3. doi: 10.1016/j.bulcan.2019.10.003. [Epub ahead of print] French.

PMID:
31831153
3.

Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de Elvira CR, Gordon D, Poirel HA, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo JD, Spellman SR, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak GW, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour RP, Kroeger N, Brand R, de Wreede LC, van Zwet E, Putter H.

Bone Marrow Transplant. 2019 Nov 21. doi: 10.1038/s41409-019-0740-9. [Epub ahead of print]

PMID:
31754251
4.

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kröger N.

Haematologica. 2020 Jan 31;105(2):297-316. doi: 10.3324/haematol.2019.229781. Print 2020.

5.

CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.

Mohty M, Gautier J, Malard F, Aljurf M, Bazarbachi A, Chabannon C, Kharfan-Dabaja MA, Savani BN, Huang H, Kenderian S, Nagler A, Perales MA.

Leukemia. 2019 Dec;33(12):2767-2778. doi: 10.1038/s41375-019-0615-5. Epub 2019 Nov 5. Review.

PMID:
31690821
6.

Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de Elvira CR, Gordon D, Poirel HA, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo JD, Spellman SR, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak GW, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour RP, Kroeger N, Brand R, de Wreede LC, van Zwet E, Putter H.

Bone Marrow Transplant. 2019 Oct 21. doi: 10.1038/s41409-019-0718-7. [Epub ahead of print] Erratum in: Bone Marrow Transplant. 2019 Nov 21;:.

PMID:
31636397
7.

A matched-pair analysis reveals marginally reduced CD34+ cell mobilization on second occasion in 27 related donors who underwent peripheral blood stem cell collection twice at the same institution.

Velier M, Granata A, Bramanti S, Calmels B, Furst S, Legrand F, Harbi S, Faucher C, Devillier R, Blaise D, Mfarrej B, Lemarie C, Chabannon C.

Transfusion. 2019 Nov;59(11):3442-3447. doi: 10.1111/trf.15545. Epub 2019 Oct 18.

PMID:
31625183
8.

Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation.

Garciaz S, N'guyen Dasi L, Finetti P, Chevalier C, Vernerey J, Poplineau M, Platet N, Audebert S, Pophillat M, Camoin L, Bertucci F, Calmels B, Récher C, Birnbaum D, Chabannon C, Vey N, Duprez E.

Clin Epigenetics. 2019 Oct 12;11(1):141. doi: 10.1186/s13148-019-0738-6.

9.

Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor.

Sureda A, Chabannon C, Masszi T, Pohlreich D, Scheid C, Thieblemont C, Wahlin BE, Sakellari I, Russell N, Janikova A, Dabrowska-Iwanicka A, Touzeau C, Esquirol A, Jantunen E, van der Werf S, Bosman P, Boumendil A, Liu Q, Celanovic M, Montoto S, Dreger P.

Bone Marrow Transplant. 2019 Sep 30. doi: 10.1038/s41409-019-0693-z. [Epub ahead of print]

PMID:
31570781
10.

Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation.

Nykolyszyn C, Granata A, Pagliardini T, Castagna L, Harbi S, Bouabdallah R, Vey N, Fürst S, Maisano V, Legrand F, Lemarié C, Calmels B, Chabannon C, Weiller PJ, Blaise D, Devillier R.

Bone Marrow Transplant. 2020 Feb;55(2):349-355. doi: 10.1038/s41409-019-0682-2. Epub 2019 Sep 18.

PMID:
31534196
11.

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor.

Morris C, Chabannon C, Masszi T, Russell N, Nahi H, Kobbe G, Krejci M, Auner HW, Pohlreich D, Hayden P, Basak GW, Lenhoff S, Schaap N, van Biezen A, Knol C, Iacobelli S, Liu Q, Celanovic M, Garderet L, Kröger N.

Bone Marrow Transplant. 2020 Feb;55(2):356-366. doi: 10.1038/s41409-019-0676-0. Epub 2019 Sep 18.

12.

Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.

Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, Chabannon C, Kuball J, Basak GW, Dufour C, Galimard JE, Polge E, Lankester A, Montoto S, Snowden JA, Styczynski J, Yakoub-Agha I, Mohty M, Nagler A.

Lancet Haematol. 2019 Nov;6(11):e573-e584. doi: 10.1016/S2352-3026(19)30158-9. Epub 2019 Aug 30.

PMID:
31477550
13.

Development of adaptive immune effector therapies in solid tumors.

Comoli P, Chabannon C, Koehl U, Lanza F, Urbano-Ispizua A, Hudecek M, Ruggeri A, Secondino S, Bonini C, Pedrazzoli P.

Ann Oncol. 2019 Nov 1;30(11):1740-1750. doi: 10.1093/annonc/mdz285.

PMID:
31435646
14.

Validation of a semi automatic device to standardize quantification of Colony-Forming Unit (CFU) on hematopoietic stem cell products.

Velier M, Chateau AL, Malenfant C, Ouffai S, Calmels B, Chabannon C, Lemarié C.

Cytotherapy. 2019 Aug;21(8):820-823. doi: 10.1016/j.jcyt.2019.06.005. Epub 2019 Jun 28.

PMID:
31257121
15.

Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma.

Mariotti J, Devillier R, Bramanti S, Giordano L, Sarina B, Furst S, Granata A, Maisano V, Pagliardini T, De Philippis C, Kogan M, Faucher C, Harbi S, Chabannon C, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D, Castagna L.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1810-1817. doi: 10.1016/j.bbmt.2019.05.017. Epub 2019 May 22.

PMID:
31128326
16.

Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.

Pagliardini T, Castagna L, Harbi S, Porta MD, Rey J, Fürst S, Bramanti S, Saillard C, Legrand F, Maisano V, Faucher C, Granata A, Hospital MA, Lining W, Weiller PJ, Calmels B, Charbonnier A, Lemarie C, Chabannon C, Vey N, Mokart D, Blaise D, Devillier R.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1803-1809. doi: 10.1016/j.bbmt.2019.05.014. Epub 2019 May 22.

PMID:
31128325
17.

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Bone Marrow Transplant. 2019 Nov;54(11):1868-1880. doi: 10.1038/s41409-019-0451-2. Epub 2019 May 15.

PMID:
31092900
18.

Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019.

Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, Corbacioglu S, Dreger P, Dufour C, Gennery AR, Kuball J, Lankester AC, Lanza F, Montoto S, Nagler A, Peffault de Latour R, Snowden JA, Styczynski J, Yakoub-Agha I, Kröger N, Mohty M; European Society for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2019 Oct;54(10):1525-1552. doi: 10.1038/s41409-019-0516-2. Epub 2019 Apr 5.

PMID:
30953028
19.

Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients.

Granata A, Fürst S, Bramanti S, Legrand F, Sarina B, Harbi S, De Philippis C, Faucher C, Chabannon C, Lemarie C, Calmels B, Mariotti J, Maisano V, Weiller PJ, Mokart D, Vey N, Bouabdallah R, Castagna L, Blaise D, Devillier R.

Bone Marrow Transplant. 2019 Nov;54(11):1730-1737. doi: 10.1038/s41409-019-0500-x. Epub 2019 Mar 19.

PMID:
30890770
20.

[Chapter 6. Legal issues and for the health system of the development of a new class of innovative therapy in oncoimmunology: the “Car-T CellS”].

Rial-Sebbag E, Chabannon C.

J Int Bioethique Ethique Sci. 2018 Jul;29(2):113-128. doi: 10.3917/jibes.292.0113. French.

PMID:
30767443
21.

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies.

Passweg JR, Baldomero H, Basak GW, Chabannon C, Corbacioglu S, Duarte R, Kuball J, Lankester A, Montoto S, de Latour RP, Snowden JA, Styczynski J, Yakoub-Agha I, Arat M, Mohty M, Kröger N; European Society for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2019 Oct;54(10):1575-1585. doi: 10.1038/s41409-019-0465-9. Epub 2019 Feb 6.

22.

[CAR-T cells: Lymphocytes that express a chimeric antigen receptor].

Chabannon C, Bouabdallah R, Fürst S, Granata A, Saillard C, Vey N, Mokart D, Fougereau E, Lemarie C, Mfarrej B, Blaise D, Calmels B.

Rev Med Interne. 2019 Aug;40(8):545-552. doi: 10.1016/j.revmed.2018.12.002. Epub 2019 Jan 25. French.

PMID:
30686549
23.
24.

The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide.

Mariotti J, Granata A, Bramanti S, Devillier R, Furst S, Sarina B, Harbi S, Legrand F, Faucher C, Weiller PJ, Chabannon C, Carlo-Stella C, Santoro A, Blaise D, Castagna L.

Bone Marrow Transplant. 2019 Jul;54(7):1164-1167. doi: 10.1038/s41409-019-0453-0. Epub 2019 Jan 24.

PMID:
30679826
25.

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Biol Blood Marrow Transplant. 2019 Mar;25(3):e76-e85. doi: 10.1016/j.bbmt.2018.12.068. Epub 2018 Dec 18.

PMID:
30576834
26.

Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting.

Bondanza A, Ruggeri L, Noviello M, Eikema DJ, Bonini C, Chabannon C, van der Werf S, van Biezen A, de Wreede LC, Crucitti L, Vago L, Merluzzi M, Massei MS, Veelken H, Koc Y, Bader P, Gruhn B, Locatelli F, Ciceri F, Toubert A, Velardi A; EBMT Cell Therapy and Immunobiology Working Party.

Bone Marrow Transplant. 2019 Jun;54(6):867-876. doi: 10.1038/s41409-018-0351-x. Epub 2018 Dec 7.

PMID:
30531916
27.

Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients.

Pagliardini T, Harbi S, Fürst S, Castagna L, Legrand F, Faucher C, Granata A, Weiller PJ, Calmels B, Lemarie C, Chabannon C, Bouabdallah R, Mokart D, Vey N, Blaise D, Devillier R.

Bone Marrow Transplant. 2019 Jul;54(7):1067-1076. doi: 10.1038/s41409-018-0387-y. Epub 2018 Nov 6.

PMID:
30401970
28.

Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3+ cells.

Cauchois R, Castagna L, Pagliardini T, Harbi S, Calmels B, Bramanti S, Granata A, Lemarie C, Maisano V, Legrand F, Fürst S, Faucher C, Weiller PJ, Chabannon C, Blaise D, Devillier R.

Br J Haematol. 2019 May;185(3):570-573. doi: 10.1111/bjh.15544. Epub 2018 Aug 20. No abstract available.

PMID:
30125934
29.

Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation.

Trento C, Bernardo ME, Nagler A, Kuçi S, Bornhäuser M, Köhl U, Strunk D, Galleu A, Sanchez-Guijo F, Gaipa G, Introna M, Bukauskas A, Le Blanc K, Apperley J, Roelofs H, Van Campenhout A, Beguin Y, Kuball J, Lazzari L, Avanzini MA, Fibbe W, Chabannon C, Bonini C, Dazzi F.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2365-2370. doi: 10.1016/j.bbmt.2018.07.015. Epub 2018 Jul 20.

30.

Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation.

Mohty M, Duarte RF, Kuball J, Bader P, Basak GW, Bonini C, Carreras E, Chabannon C, Dufour C, Gennery A, Lankester A, Lanza F, Ljungman P, Montoto S, Nagler A, Snowden JA, Styczynski J, Sureda A, Kröger N.

Bone Marrow Transplant. 2018 Dec;53(12):1548-1552. doi: 10.1038/s41409-018-0190-9. Epub 2018 May 2.

PMID:
29720705
31.

Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP.

Greco R, Ciceri F, Noviello M, Bondanza A, Vago L, Oliveira G, Peccatori J, Cieri N, Ruggeri A, Koehl U, Fleischhauer K, Rocha V, Dazzi F, van der Werf SM, Eikema DJ, Terwel SR, Kuball J, Toubert A, Chabannon C, Bonini C; EBMT Cellular Therapy and Immunobiology Working Party (CTIWP).

Bone Marrow Transplant. 2018 Sep;53(9):1201-1205. doi: 10.1038/s41409-018-0167-8. Epub 2018 Apr 17. No abstract available.

PMID:
29666449
32.

Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies.

Chabannon C, Kuball J, Bondanza A, Dazzi F, Pedrazzoli P, Toubert A, Ruggeri A, Fleischhauer K, Bonini C.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaap9630. doi: 10.1126/scitranslmed.aap9630. Review.

PMID:
29643233
33.

Considerations pertaining to cell collection and administration of industry-manufactured autologous CAR-T cells, in relation to French healthcare organization and regulations.

Chabannon C, Larghero J.

Curr Res Transl Med. 2018 May;66(2):59-61. doi: 10.1016/j.retram.2018.03.002. Epub 2018 Apr 4.

PMID:
29625832
34.

Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years.

Debals-Gonthier M, Siani C, Faucher C, Touzani R, Lemarié-Basset C, Chabannon C, Furst S, Devillier R, Harbi S, Castagna L, Caymaris L, Blaise D, Le Corroller Soriano AG.

Bone Marrow Transplant. 2018 Sep;53(9):1096-1104. doi: 10.1038/s41409-018-0133-5. Epub 2018 Mar 9.

PMID:
29523885
35.

HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison.

Devillier R, Legrand F, Rey J, Castagna L, Fürst S, Granata A, Charbonnier A, Harbi S, d'Incan E, Pagliardini T, Faucher C, Lemarie C, Saillard C, Calmels B, Mohty B, Maisano V, Weiller PJ, Chabannon C, Vey N, Blaise D.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1449-1454. doi: 10.1016/j.bbmt.2018.02.002. Epub 2018 Feb 12.

36.

Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT.

Castagna L, Boubdallah R, Furst S, Coso D, El Cheikh J, Faucher C, Crocchiolo R, Granata A, Chabannon C, Lemarié C, Calmels B, Boher JM, Mohty M, Blaise D.

Bone Marrow Transplant. 2018 Feb;53(2):234. doi: 10.1038/bmt.2018.1.

PMID:
29410535
37.

Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT).

Necchi A, Lo Vullo S, Secondino S, Rosti G, Badoglio M, Giannatempo P, Raggi D, Lanza F, Chabannon C, Bonini C, Mariani L, Pedrazzoli P; European Society for Blood and Marrow Transplantation, Cellular Therapy & Immunobiology Working Party – Solid Tumor sub-committee.

Bone Marrow Transplant. 2018 Jun;53(6):722-728. doi: 10.1038/s41409-017-0079-z. Epub 2018 Jan 24.

PMID:
29367713
38.

Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation.

Holbro A, Baldomero H, Lanza F, Chabannon C, Snowden JA, Buser A, Infanti L, Worel N, Sureda A, Badoglio M, Passweg J, Bonini C; Cellular Therapy & Immunobiology Working Party of the European Society for Blood & Marrow Transplantation (EBMT) and the Joint Accreditation Committee International Society for Cellular Therapy & EBMT (JACIE).

Cytotherapy. 2018 Mar;20(3):453-460. doi: 10.1016/j.jcyt.2017.12.005. Epub 2018 Jan 17.

PMID:
29352666
39.

From clinical proof-of-concept to commercialization of CAR T cells.

Calmels B, Mfarrej B, Chabannon C.

Drug Discov Today. 2018 Apr;23(4):758-762. doi: 10.1016/j.drudis.2018.01.024. Epub 2018 Jan 6. Review.

PMID:
29317339
40.

Early prognostic factors in septic shock cancer patients: a prospective study with a proteomic approach.

Mokart D, Saillard C, Zemmour C, Bisbal M, Sannini A, Chow-Chine L, Brun JP, Faucher M, Boher JM, Toiron Y, Chabannon C, Borg JP, Gonçalves A, Camoin L.

Acta Anaesthesiol Scand. 2018 Apr;62(4):493-503. doi: 10.1111/aas.13060. Epub 2018 Jan 7.

PMID:
29315472
41.

Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma.

Mariotti J, Bramanti S, Devillier R, Furst S, El Cheikh J, Sarina B, Granata A, Faucher C, Harbi S, Morabito L, Weiller PJ, Chabannon C, Mokart J, Mineri R, Carlo-Stella C, Santoro A, Blaise D, Castagna L.

Bone Marrow Transplant. 2018 Mar;53(3):366-370. doi: 10.1038/s41409-017-0032-1. Epub 2017 Dec 21. No abstract available.

PMID:
29269800
42.

Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis.

Mohty M, Azar N, Chabannon C, Le Gouill S, Karlin L, Farina L, Milkovich G, Ostermann H, Glaß B, Noppeney R, Kron F, Kron A, Hübel K.

Bone Marrow Transplant. 2018 Mar;53(3):246-254. doi: 10.1038/s41409-017-0033-0. Epub 2017 Dec 18.

PMID:
29255168
43.

Killer Cell Immunoglobulin-Like Receptor-Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide.

Wanquet A, Bramanti S, Harbi S, Fürst S, Legrand F, Faucher C, Granata A, Calmels B, Lemarie C, Picard C, Chabannon C, Weiller PJ, Castagna L, Blaise D, Devillier R.

Biol Blood Marrow Transplant. 2018 Mar;24(3):549-554. doi: 10.1016/j.bbmt.2017.11.042. Epub 2017 Dec 13.

44.

Jon van Rood (1926-2017).

Mueller C, Bonini C, Foeken L, Chabannon C, Bondanza A, Fleischhauer K, Velardi A, Kröger N, Kuball J, Mohty M.

Bone Marrow Transplant. 2017 Dec;52(12):1587. doi: 10.1038/bmt.2017.242. No abstract available.

PMID:
29209062
45.

CAR-T cells: the narrow path between hope and bankruptcy?

Chabannon C, Kuball J, Mcgrath E, Bader P, Dufour C, Lankester A, Basak GW, Montoto S, Nagler A, Snowden JA, Styczynski J, Duarte RF, Kröger N, Mohty M.

Bone Marrow Transplant. 2017 Dec;52(12):1588-1589. doi: 10.1038/bmt.2017.241. No abstract available.

PMID:
29209061
46.

T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors.

Mariotti J, Devillier R, Bramanti S, Sarina B, Furst S, Granata A, Faucher C, Harbi S, Morabito L, Chabannon C, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D, Castagna L.

Biol Blood Marrow Transplant. 2018 Mar;24(3):627-632. doi: 10.1016/j.bbmt.2017.11.030. Epub 2017 Nov 29.

47.

[Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Yakoub-Agha I, Ferrand C, Chalandon Y, Ballot C, Castilla Llorente C, Deschamps M, Gauthier J, Labalette M, Larghero J, Maheux C, Moreau AS, Varlet P, Pétillon MO, Pinturaud M, Rubio MT, Chabannon C.

Bull Cancer. 2017 Dec;104(12S):S43-S58. doi: 10.1016/j.bulcan.2017.10.017. Epub 2017 Nov 23. French.

PMID:
29174320
48.

[Non eligibility criteria for hematopoietic stem cell donors: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Boiron JM, Garban F, Audat F, Ader V, Andreu H, Aubrège-Bouvier C, Borel C, Huynh P, Nacimento F, Yakoub-Agha I, Chabannon C.

Bull Cancer. 2017 Dec;104(12S):S76-S83. doi: 10.1016/j.bulcan.2017.06.022. Epub 2017 Nov 22. French.

PMID:
29173975
49.

Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in thawed hematopoietic progenitor cell grafts.

Mfarrej B, Bouchet G, Couquiaud J, Regimbaud L, Binninger S, Mercier M, Lemarié C, Houzé P, Chabannon C, Calmels B.

Cytotherapy. 2017 Dec;19(12):1501-1508. doi: 10.1016/j.jcyt.2017.09.001. Epub 2017 Oct 14.

50.

[The biological complexity of Polycomb group proteins: the case of EZH2].

Koubi M, Chabannon C, Duprez E.

Med Sci (Paris). 2017 May;33(5):499-505. doi: 10.1051/medsci/20173305013. Epub 2017 Jun 14. Review. French.

Supplemental Content

Loading ...
Support Center